January 2022 updates to the website
20 January 2022
The website has now been updated following January's LSCMMG
The following guidelines have been added/updated:
Rheumatoid Arthritis High Cost Drugs pathway - updated
Guidelines for the prescribing of nutritional supplements post bariatric surgery - updated
Inclisiran TA 733 position statement - new
The following Items have been updated and added to the website following the latest Strategic Commissioning Committee (SCC) Meeting:
Inclisiran - treating primary hypercholesterolaemia or mixed dyslipidaemia (NICE TA733)
Upadacitinib - treating moderate rheumatoid arthritis (NICE TA744)
Glycopyrronium oral - hypersalivation in adults and children (non-Parkinson’s disease)
Clonidine 25 mcg tablets - Vasomotor symptoms (VMS) associated with menopause
The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:
Cenobamate - treating focal onset seizures in epilepsy (NICE TA753)
Trixeo Aerosphere - a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist
Bevespi Aerosphere - a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)